Granted Patent
B2
US 12,240,875 · App. 16/213,422 · Granted Mar 4, 2025
Use of FCRN antagonists for treatment of generalized myasthenia gravis
Inventors:
Johannes De Haard (Oudelande, NL); Torsten Dreier (Sint-Martens-Latem, BE); Peter Ulrichts (Destelbergen, BE); Antonio Guglietta (Barcelona, ES); Nicolas Leupin (Zurich, CH)
Assignee:
argenx BV
C07K14/4703A61P37/00C07K14/70535C07K16/00A61K9/0019A61K38/00A61K45/06A61K47/183A61K47/26C07K2317/52C07K2317/526C07K2317/92C07K2317/94C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided are novel methods of treating generalized myasthenia gravis in a subject. These methods generally comprise administering to the subject an effective amount of an isolated FcRn antagonist. In certain embodiments the FcRn antagonist binds to FcRn with increased affinity and reduced pH dependence relative to native Fc region.
Claims (24)
1. A method of treating generalized myasthenia gravis (gMG) in a subject in need thereof comprising intravenously administering to the subject an FcRn antagonist consisting of a variant Fc region, wherein the variant Fc region consists of two Fc domains which form a homodimer, wherein the amino acid sequence of each of the Fc domains consists of SEQ ID NO: 2 or SEQ ID NO: 3, wherein the FcRn antagonist is administered using a phased dosing schedule comprising an induction phase followed by a maintenance phase,
wherein the induction phase lasts for 7, 8, 9, or 10 weeks and consists of 4 doses of 10 mg/kg of the FcRn antagonist, wherein each dose of the FcRn antagonist is administered once weekly during weeks 1, 2, 3, and 4 of the induction phase;
wherein the maintenance phase comprises one or more cycles as needed based on clinical need thereafter, wherein each cycle consists of 4 doses of 10 mg/kg of the FcRn antagonist within 1 month, wherein each dose of each cycle is administered once weekly; and
wherein the subject is positive for auto-antibodies binding to nicotinic acetylcholine receptor (anti-AChR).
2. The method of claim 1 , wherein the amino acid sequence of each of the Fc domains consists of SEQ ID NO: 2.
3. The method of claim 1 , wherein the FcRn antagonist is efgartigimod.
4. The method of claim 1 , wherein the amino acid sequence of each of the Fc domains consists of SEQ ID NO: 3.
5. The method of claim 1 , wherein the subject, prior to first administration of the FcRn antagonist, has confirmed diagnosis gMG, has Class II-IVa disease according to the Myasthenia Gravis Foundation of America (MGFA) classification system, and has an MG-ADL score of at least 5 with more than 50% of the score attributable to non-ocular items.
6. The method of claim 1 , wherein the gMG is not responsive to a standard myasthenia gravis therapy selected from the group consisting of intravenous immunoglobulin (IVIg), plasmapheresis, azathioprine, non-steroidal immunosuppressant drugs, steroids, cholinesterase inhibitors, immunoadsorption, and eculizumab.
7. The method of claim 1 , wherein administration of the FcRn antagonist improves one or more therapeutic evaluation scores in the subject selected from the group consisting of Quantitative Myasthenia Gravis (QMG) score and Myasthenia Gravis activities of daily living (MG-ADL) score.
8. The method of claim 7 , wherein the QMG score is decreased by at least 3 points at day 8, 15, 22, 29, or 36 compared to a baseline QMG score as measured prior to administration of the FcRn antagonist at day 1.
9. The method of claim 7 , wherein the MG-ADL score is decreased by at least 2 points at day 8, 15, 22, 29, or 36 compared to a baseline MG-ADL score as measured prior to administration of the FcRn antagonist at day 1.
10. The method of claim 1 , wherein the subject exhibits a clinically meaningful improvement in MG-ADL score.
11. The method of claim 10 , wherein the subject exhibits a clinically meaningful improvement in MG-ADL score no later than 1 week after the last of the 4 weekly administrations of the induction phase or no later than 1 week after the last of the 4 weekly administrations of a cycle during the maintenance phase.
12. The method of claim 10 , wherein the clinically meaningful improvement in MG-ADL score is a 2-point or greater reduction in score.
13. The method of claim 1 , wherein the subject exhibits an improvement of at least 2 points in MG-ADL score at day 29 or 36 compared to a baseline MG-ADL score as measured prior to administration of the FcRn antagonist at day 1.
14. The method of claim 1 , wherein the subject exhibits an improvement of at least 2 points in MG-ADL score for a period of at least 6 weeks.
15. The method of claim 1 , wherein the subject exhibits an MG-ADL response, wherein an MG-ADL response is a reduction of >2 points in MG-ADL score compared to treatment cycle baseline, for at least 4 consecutive weeks, wherein the first of the reductions occurs at the latest 1 week after the last administration of the treatment cycle, wherein the treatment cycle comprises 4 weekly administrations of the FcRn antagonist.
16. The method of claim 1 , wherein the subject exhibits a QMG response, wherein a QMG response is a reduction of >3 points in QMG score compared to treatment cycle baseline, for at least 4 consecutive weeks, wherein the first of the reductions occurs at the latest 1 week after the last administration of the treatment cycle, wherein the treatment cycle comprises 4 weekly administrations of the FcRn antagonist.
17. The method of claim 1 , wherein the doses of the induction phase are administered on days 1, 8, 15, and 22.
18. The method of claim 1 , wherein the induction phase lasts for 7 weeks.
19. The method of claim 1 , wherein the induction phase lasts for 8 weeks.
20. The method of claim 1 , wherein each cycle of the maintenance phase lasts for 8 weeks, and wherein the 4 doses of each cycle of the maintenance phase are administered during weeks 1, 2, 3, and 4 of each 8-week cycle.
21. The method of claim 1 , wherein the clinical need is determined based on a total MG-ADL score of ≥5 in the subject or a total MG-ADL score of ≥5 with more than 50% of the score due to non-ocular symptoms in the subject.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 6, 2019
From: DE HAARD, JOHANNES; DREIER, TORSTEN; ULRICHTS, PETER; GUGLIETTA, ANTONIO; LEUPIN, NICOLAS
To: ARGENX BVBA
Reel/Frame 050933/0261 →
Continuity (2)
Provisional Application
62596562
· Dec 8, 2017
References Cited (400)
US 5326856A
· Coughlin et al.
· 1994
[cited by applicant]
US 5624821A
· Winter et al.
· 1997
[cited by applicant]
US 5648260A
· Winter et al.
· 1997
[cited by applicant]
US 5677425A
· Bodmer et al.
· 1997
[cited by applicant]
US 5869046A
· Presta et al.
· 1999
[cited by applicant]
US 5885573A
· Bluestone et al.
· 1999
[cited by applicant]
US 6121022A
· Presta et al.
· 2000
[cited by applicant]
US 6165745A
· Ward et al.
· 2000
[cited by applicant]
US 6194551B1
· Idusogie et al.
· 2001
[cited by applicant]
US 6277375B1
· Ward
· 2001
[cited by applicant]
US 6528624B1
· Idusogie et al.
· 2003
[cited by applicant]
US 6737056B1
· Presta et al.
· 2004
[cited by applicant]
US 6821505B2
· Ward
· 2004
[cited by applicant]
US 6992234B2
· Roopenian et al.
· 2006
[cited by applicant]
US 7083784B2
· Dall'Acqua et al.
· 2006
[cited by applicant]
US 7183387B1
· Presta
· 2007
[cited by applicant]
US 7670600B2
· Dall'Acqua et al.
· 2010
[cited by applicant]
US 7683784B2
· Nagai et al.
· 2010
[cited by applicant]
US 7704497B2
· Dall'Acqua et al.
· 2010
[cited by applicant]
US 8012476B2
· Dall'Acqua et al.
· 2011
[cited by applicant]
US 8021856B2
· Umaña et al.
· 2011
[cited by applicant]
US 8067232B2
· Kanda
· 2011
[cited by applicant]
US 8101186B2
· Mezo et al.
· 2012
[cited by applicant]
US 8163881B2
· Ober et al.
· 2012
[cited by applicant]
US 8195661B2
· Asawaree
· 2012
[cited by applicant]
US 8216805B2
· Carter et al.
· 2012
[cited by applicant]
US 8273351B2
· Tenhoor et al.
· 2012
[cited by applicant]
US 8323962B2
· Dall'Acqua et al.
· 2012
[cited by applicant]
US 8475792B2
· Dall'Acqua et al.
· 2013
[cited by applicant]
US 8680237B2
· Strome et al.
· 2014
[cited by applicant]
US 8795661B2
· Dall'Acqua et al.
· 2014
[cited by applicant]
US 8815246B2
· Tenhoor et al.
· 2014
[cited by applicant]
US 8834871B2
· Ober
· 2014
[cited by applicant]
US 9260520B2
· Tenhoor et al.
· 2016
[cited by applicant]
US 20040002587A1
· Watkins et al.
· 2004
[cited by applicant]
US 20040010124A1
· Johnson et al.
· 2004
[cited by applicant]
US 20040047862A1
· Lazarus et al.
· 2004
[cited by applicant]
US 20050053598A1
· Burke
· 2005
[cited by examiner]
US 20060210557A1
· Luisi et al.
· 2006
[cited by applicant]
US 20090252729A1
· Farrington et al.
· 2009
[cited by applicant]
US 20110081345A1
· Moore
· 2011
[cited by applicant]
US 20110243966A1
· Farrington et al.
· 2011
[cited by applicant]
US 20140302028A1
· Zha et al.
· 2014
[cited by applicant]
US 20160264669A1
· Ulrichts
· 2016
[cited by examiner]
US 20220275035A1
· Ulrichts et al.
· 2022
[cited by applicant]
US 20230357382A1
· Borgions et al.
· 2023
[cited by applicant]
EP 0227110A2
· 1987
[cited by applicant]
EP 0904107B1
· 1999
[cited by applicant]
EP 1355919B1
· 2010
[cited by applicant]
EP 1896503B1
· 2014
[cited by applicant]
EP 3087095B1
· 2019
[cited by applicant]
JP 2013507128A
· 2013
[cited by applicant]
WO WO1994029351A2
· 1994
[cited by applicant]
WO WO1996022024A1
· 1996
[cited by applicant]
WO WO1997034631A1
· 1997
[cited by applicant]
WO WO1999004813A1
· 1999
[cited by applicant]
WO WO1999058572A1
· 1999
[cited by applicant]
WO WO2000042072A2
· 2000
[cited by applicant]
WO WO2001058957A2
· 2001
[cited by applicant]
WO WO2002043658A2
· 2002
[cited by applicant]
WO WO2002060919A2
· 2002
[cited by applicant]
WO WO2004016750A2
· 2004
[cited by applicant]
WO WO2004029207A2
· 2004
[cited by applicant]
WO WO2004035752A2
· 2004
[cited by applicant]
WO 2004063343A2
· 2004
[cited by applicant]
WO WO2004063351A2
· 2004
[cited by applicant]
WO WO2004099249A2
· 2004
[cited by applicant]
WO WO2005040217A2
· 2005
[cited by applicant]
WO WO2006118772A2
· 2006
[cited by applicant]
WO WO2006130834A2
· 2006
[cited by applicant]
WO WO2007098420A2
· 2007
[cited by applicant]
WO WO2009100105A2
· 2009
[cited by applicant]
WO WO2009131702A2
· 2009
[cited by applicant]
WO WO2010014909A1
· 2010
[cited by applicant]
WO WO2010106180A2
· 2010
[cited by applicant]
WO WO2010111254A1
· 2010
[cited by applicant]
WO WO2011044368A1
· 2011
[cited by applicant]
WO WO2011080209A2
· 2011
[cited by applicant]
WO WO2012167039A1
· 2012
[cited by applicant]
WO WO2013063186A2
· 2013
[cited by applicant]
WO WO2013074598A1
· 2013
[cited by applicant]
WO WO2013100702A1
· 2013
[cited by applicant]
WO 2013166604A1
· 2013
[cited by applicant]
WO 2014008391A1
· 2014
[cited by applicant]
WO WO2014019727A1
· 2014
[cited by applicant]
WO 2014140366A1
· 2014
[cited by applicant]
WO WO2014204280A1
· 2014
[cited by applicant]
WO 2015071330A1
· 2015
[cited by applicant]
WO 2015073721A1
· 2015
[cited by applicant]
WO WO2015081073A2
· 2015
[cited by applicant]
WO WO2015100299A1
· 2015
[cited by applicant]
WO WO2016042083A1
· 2016
[cited by applicant]
WO WO2016123521A2
· 2016
[cited by applicant]
WO WO2016142782A1
· 2016
[cited by applicant]
WO WO2016180765A1
· 2016
[cited by applicant]
WO WO2016183352A1
· 2016
[cited by applicant]
WO WO2017012959A1
· 2017
[cited by applicant]
WO WO2017121330A1
· 2017
[cited by applicant]
WO 2017189959A1
· 2017
[cited by applicant]
WO 2018023136A1
· 2018
[cited by applicant]
WO WO2018083122A1
· 2018
[cited by applicant]
WO 2019110823A1
· 2019
[cited by applicant]
WO WO2019118791A1
· 2019
[cited by applicant]
WO 2019234713A2
· 2019
[cited by applicant]
WO 2020078905A1
· 2020
[cited by applicant]
WO WO2020097099A1
· 2020
[cited by applicant]
WO 2020227515A1
· 2020
[cited by applicant]
WO WO2020236695A1
· 2020
[cited by applicant]
WO 2020245420A1
· 2020
[cited by applicant]
WO 2021022249A1
· 2021
[cited by applicant]
WO 2020245420A9
· 2021
[cited by applicant]
WO 2021140202A1
· 2021
[cited by applicant]
WO 2021216756A2
· 2021
[cited by applicant]
WO 2022098955A1
· 2022
[cited by applicant]
WO 2023012515A2
· 2023
[cited by applicant]
WO 2023135321A1
· 2023
[cited by applicant]
WO 2023156614A1
· 2023
[cited by applicant]
WO 2023209036A1
· 2023
[cited by applicant]
WO 2023242361A1
· 2023
[cited by applicant]
WO 2023242362A1
· 2023
[cited by applicant]
WO 2023242371A1
· 2023
[cited by applicant]
WO 2023242372A1
· 2023
[cited by applicant]
WO 2024100453A1
· 2024
[cited by applicant]
WO 2024100455A1
· 2024
[cited by applicant]
WO 2024105445A2
· 2024
[cited by applicant]
WO 2024147074A1
· 2024
[cited by applicant]
Jaretzki III et al. Ann Thorac Srg 2000, 70:327-34. (Year: 2000).
[cited by examiner]
Kang et al. BioProcess International, Apr. 12, 2016, pp. 40-44. (Year: 2016).
[cited by examiner]
Anonymous: “A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients with ITP”, clinicaltrials.gov Identifier NCT03102593, Apr. 6, 2017, pp. 1-7.
[cited by applicant]
Bussel et al., “A Randomized, Double-Blind Study of Romiplostim to Determine its Safety and Efficacy in Children with Immune Thrombocytopenia”, Blood, vol. 118, No. 1, Jul. 7, 2011, pp. 28-36.
[cited by applicant]
Bussel et al., “Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP) : Romiplostim in Pediatric ITP” Pediatric Blood and Cancer, Feb. 1, 2015, vol. 62, No…
[cited by applicant]
De Haard et al., “Advancing ARGX-113 and ARGX-110 to Clinical Proof of Concept”, Dec. 4, 2016, pp. 1-575.
[cited by applicant]
Eddleston et al., “Blockade of the Neonatal Fe Receptor (FcRn) Represents an Effective Mechanism for the Removal of Pathogenic Autoantibodies in Primary Immune Thrombocytopenia”, Database Biosis [Online] Biosciences Inf…
[cited by applicant]
International Search Report and Written Opinion in related PCT International Patent Application No. PCT/IB2019/054786, mailed Dec. 18, 2019.
[cited by applicant]
International Preliminary Report on Patentability in related PCT International Patent Application No. PCT/IB2019/054786, mailed Dec. 8, 2020.
[cited by applicant]
International Search Report with Written Opinion in related PCT International Patent Application No. PCT/IB2016/000398, mailed Aug. 22, 2016.
[cited by applicant]
International Preliminary Report on Patentability in related PCT International Patent Application No. PCT/IB2016/000398, mailed Sep. 12, 2017.
[cited by applicant]
Swiss Webster Mice, by TACONIC, Aug. 23, 2018, pp. 1-7.
[cited by applicant]
Ulrichts et al., “ARGX-113, a Novel Fc-Based Approach for Antibody-Induced Pathologies Such as Primary Immune Thrombocytopenia”, Blood, 2016, vol. 128, No. 22: 4919.
[cited by applicant]
Abdiche et al. (2015) “The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity,” mAbs, 7(2):331-343.
[cited by applicant]
Akilesh et al. (2004) “The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease,” J. Clin. Invest. 113(9):1328-1333.
[cited by applicant]
Alegre et al. (1994) “A Non-Activating “Humanized” Anti-CD3 Monoclonal Antibody Retains Immunosuppressive Properties In Vivo,” Transplantation, 57(11):1537-1543.
[cited by applicant]
Alipour-Faz et al. (2017) “A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients,” Acta Neurol Belg, 117:245-249.
[cited by applicant]
Andersen et al. (2012) “Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor,” Nat. Commun. 3:610. pp. 1-9.
[cited by applicant]
Anonymous (2016) “Argenx announces initial results from Phase 1 multiple ascending dose (MAD) study of ARGX-113 in healthy volunteers—Argenx,” 1 pg.
[cited by applicant]
ARGEN-X “ARGX-113,” http://www.argen-x.com. Accessible on the Internet at URL: http://www.argen-x.com/en-GB/content/argx-113/22. [Last Accessed Jul. 5, 2017].
[cited by applicant]
ARGEN-X (Oct. 2013) “An Emerging Antibody Force: Company Presentation,” Presentation Slides.
[cited by applicant]
ARGEN-X (Oct. 2013) “ARGX-113: Development Opportunity in Autoimmunity,” Presentation Slides.
[cited by applicant]
ARGEN-X N.V. (Apr. 24, 2014) “arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders,” Press Release. arGEN-X. Accessible on the Internet at URL: http://www.argen-x.com/en-GB/news-internal/argen…
[cited by applicant]
ARGEN-X N.V. (Jun. 20, 2014) Prospectus for Public Offering of arGEN-X N.V.
[cited by applicant]
ARGEN-X N.V. (Aug. 19, 2014) “arGEN-X announces positive preclinical results for ARGX-113,” Press Release. EURONEXT. Accessible on the Internet at URL: https://www.euronext.com/nl/node/506652. [Last Accessed Aug. 1, 201…
[cited by applicant]
Armour et al. (1999) “Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities,” Eur. J. Immunol. 29:2613-2624.
[cited by applicant]
Ballow (1991) “Mechanism of action of IVIG therapy and potential uses in autoimmune connective tissue diseases,” Cancer 68:1430-1436.
[cited by applicant]
Barth et al. (2011) “Comparison of IVIg and PLEX in patients with myasthenia gravis,” Neurology. 76(23):2017-2023.
[cited by applicant]
Blanchette et al. (1984) “Intensive plasma exchange therapy in ten patients with idiopathic thrombocytopenia purpura,” Transfusion. 24(5):388-394.
[cited by applicant]
Burns (2012) “Of Mice and Children: Lessons From a Kawasaki Mouse Model,” Circulation. 125:1480-1481.
[cited by applicant]
Burns et al. (2010) “History of outcome measures for myasthenia gravis,” Muscle Nerve. 42(1):5-13.
[cited by applicant]
Challa (2013) “Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis,” mAbs, 5(5):655-659.
[cited by applicant]
Chaudhury et al. (2003) “The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan,” J. Exp. Med. 197(3):315-322.
[cited by applicant]
Cipriani et al. (2009) “MET as a target for treatment of chest tumor,” Lung Cancer. 63(2):169-179.
[cited by applicant]
Clarkson et al. (1986) “Treatment of Refractory Immune Thrombocytopeniarpura with an Anti-Fcgamma-Receptor Antibody,” New England Journal of Medicine. 314(9):1236-1239.
[cited by applicant]
Coetzee et al. (2000) “The Effect of Monoclonal Anti-human-platelet Antibodies on Platelet Kinetics in a Baboon Model: IgG Subclass Dependency,” Thromb. Haemost. 83:148-156.
[cited by applicant]
Crow et al. (2008) “The Mechanisms of Action of Intravenous Immunoglobulin and Polyclonal Anti-D Immunoglobulin in the Amelioration of Immune Thrombocytopenia Purpura: What Do We Really Know?” Transfusion Medicine Revie…
[cited by applicant]
Crow et al. (2011) “The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody-mediated amelioration of murine immune thrombocytopenia,” Blood. 118:6403-6406.
[cited by applicant]
Darabi et al. (2006) “Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature,” Transfusion. 46(5):741-753.
[cited by applicant]
Debre et al. (1993) “Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenia purpura,” Lancet. 342(8877):945-949.
[cited by applicant]
Deng et al. (2007) “Pharmacokinetic/pharmacodynamic modeling of IVIG effects in a murine model of immune thrombocytopenia,” J. Pharm. Sci. 96(6):1625-1637.
[cited by applicant]
Duncan et al. (1988) “Localization of the binding site for the human high-affinity Fc receptor on IgG,” Nature, 332:563-564.
[cited by applicant]
Edelman et al. (1969) “The covalent structure of an entire gammaG immunoglobulin molecule,” The Journal of Immunology, 63:5335-5342.
[cited by applicant]
El-Salem et al. (2014) “Treatment of MuSK-Associated Myasthenia Gravis,” Curr. Treat. Options Neurol., 16:283, 17 pages.
[cited by applicant]
Eymard et al. (2009) “[Antibodies in myasthenia gravis],” Rev. Neurol. (Paris). 165(2):137-143.
[cited by applicant]
Federico et al. (2000) “Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study,” Neurology. 55:1256-1262.
[cited by applicant]
Flaherty et al. (Oct. 24, 2011) “Nonclinical evaluation of GMA161—an antihuman CD16 (FORM) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice,” Toxicological Sciences. 125(1):299-309.
[cited by applicant]
Frusho et al. (1984) “High-dose intravenous gammaglobulin for Kawasaki disease,” Lancet. 2:1055-1058.
[cited by applicant]
Gan et al. (2009) “Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery,” Traffic. 10:600-614.
[cited by applicant]
Garcia et al. (2001) “Kinetics and thermodynamics of T cell receptor-autoantigen interactions in murine experimental autoimmune encephalomyelitis,” Proc. Natl. Acad. Sci. USA. 98:6818-6823.
[cited by applicant]
Genbank Database [online] (Jul. 2, 2016) “
[cited by applicant]
Ghetie et al. (1996) “Abnormally short serum half lives of IgGs in beta2-microglobulin deficient mice,” Eur. J. Immunol. 26:690-696.
[cited by applicant]
Ghetie et al. (1997) “Increasing the serum persistence of an IgG fragment by random mutagenesis,” Nature Biotech. 15:637-640.
[cited by applicant]
Ghetie et al. (2002) “Transcytosis and catabolismof antibody,” Immunol. Res. 25(2):97-113.
[cited by applicant]
Gilhus et al. (2011) “Myasthenia Gravis: A Review of Available Treatment Approaches,” Autoimmune Diseases, Article ID 847393, 6 pages.
[cited by applicant]
Grau (Sep. 21, 2011) “IgG core a-fucosylation and its impact on FcγRIIIa binding,” Roche Glycart AG. In; MipTec 2011, Basel, Switzerland.
[cited by applicant]
Grevys et al. (Apr. 22, 2015) “Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions,” J Immunol. 194(11):5497-5508.
[cited by applicant]
Guptill et al. (Aug. 11, 2016) “Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis,” Autoimmunity. 49(7):472-479.
[cited by applicant]
Hansen et al. (2002) “Intravenous Immunoglobulin Mediates an Increase in Anti-Platelet Antibody Clearance via the FcRn Receptor,” Thromb. Haemost. 88:898-899.
[cited by applicant]
Hanson (2014) “The role of the immunoglobulin G1 Fc N-glycan in FcγRIIIa affinity,” Thesis for partial fulfillment of the degree of Master of Science. Iowa State University. Paper 14135.
[cited by applicant]
Howard et al. (Apr. 30, 2013) “A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis,” Muscle Nerve. 48(1):76-84.
[cited by applicant]
Huang et al. (2005) “The central residues of a T cell receptor sequence motif are key determinants of autoantigen recognition in murine experimental autoimmune encephalomyelitis,” Eur. J. Immunol. 35:299-304.
[cited by applicant]
Hutchins et al. (1995) “Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma4 variant of Campath-1H,” Proc. Natl. Acad. Sci., USA, 92:11980-11984.
[cited by applicant]
Idusogie et al. (2000) “Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc,” J. Immunol., 164:4178-4184.
[cited by applicant]
Idusogie et al. (2001) “Engineered Antibodies with Increased Activity to Recruit Complement,” J. Immunol., 166:2571-2575.
[cited by applicant]
Imbach et al. (1981) “High-dose intravenous gammaglobulin for idiopathic thrombocytopeni purpura in childhood,” The Lancet, 1228-1231.
[cited by applicant]
Imbach et al. (1985) “Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenia purpura in childhood,” The Lancet, 464-468.
[cited by applicant]
Imbach et al. (2009) “Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders,” Vox Sanguinis, 10 pages.
[cited by applicant]
Imbach, Paul (2012) “Treatment of immune thrombocytopenia with intravenous immunoglobulin and insights for other diseases,” Swiss Medical Weekly, 10 pages.
[cited by applicant]
International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/EP2013/068399, issued Mar. 10, 2015.
[cited by applicant]
International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/US2014/072087, issued Jun. 28, 2016.
[cited by applicant]
International Search Report and Written Opinion corresponding to International Patent Application PCT/EP2017/077966, mailed Jan. 29, 2018.
[cited by applicant]
International Search Report corresponding to International Patent Application No. PCT/EP2013/068399, mailed Apr. 9, 2014.
[cited by applicant]
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2014/072087, mailed May 12, 2015.
[cited by applicant]
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2018/084034, mailed Feb. 18, 2019.
[cited by applicant]
Jacob et al. (2012) “Presence and Pathogenic Relevance of Antibodies to Clustered Acetylcholine Receptor in Ocular and Generalized Myasthenia Gravis,” Arch Neurol., 69(8):994-1001.
[cited by applicant]
Jain et al. (Aug. 20, 2012) “Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenia purpura in mice,” Arthritis Research & Therapy 14:R192.…
[cited by applicant]
Jefferis et al. (1995) “Recognition sites on human IgG for Fcgamma receptors: the role of glycosylation,” Immunology Letters, 44:111-117.
[cited by applicant]
Jefferis et al. (1996) “Modulation of Fc(gamma)R and human complement activation by IgG3-core oligosaccharide interactions,” Immunol. Lett. 54:101-104.
[cited by applicant]
Jefferis et al. (2002) “Interaction sites on human IgG-Fc for FcgammaR: current models,” Immunology Letters, 82:57-65.
[cited by applicant]
Junghans et al. (1996) “The protection receptor for IgG catabolismis the beta2-microglobulin-containing neonatal intestinal transport receptor,” Proc. Natl. Acad. Sci. USA. 93:5512-5516.
[cited by applicant]
Junghans (1997) “Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolismfor IgG,” Immunologic Research. 16(1):29-57.
[cited by applicant]
Kanda et al. (2006) “Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types,” Glycobiol. 17(1): …
[cited by applicant]
Kim et al. (1999) “Mapping of the site on human IgG1 for binding of the MHC class I related receptor, FcRn,” Eur. J. Immunol. 29:2819-2825.
[cited by applicant]
Law et al. (1997) “High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenia purpura,” N. Engl. J. Med. 336:1494-1498.
[cited by applicant]
Li et al. (2005) “Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases,” J. Clin. Invest. 115(12):3440-3450.
[cited by applicant]
Liu et al. (2007) “Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade,” J. Immunol. 178(8):5390-5398.
[cited by applicant]
Liu et al. (2009) “Comparing the Autoantibody Levels and Clinical Efficacy of Double Filtration Plasmapheresis, Immunoadsorption, and Intravenous Immunoglobulin for the Treatment of Late-Onset Myasthenia Gravis,” Therap…
[cited by applicant]
Low et al. (2009) “Inhibitors of the FcRn:IgG Protein-Protein Interaction,” AAPS Journal. 11(3):432-434.
[cited by applicant]
Lund et al. (1991) “Human Fc gamma RI and Fc gamma RII interact with distinct but overlapping sites on human IgG,” J. Immunol. 147:2657-2662.
[cited by applicant]
Lund et al. (1992) “Multiple binding sites on the CH2 Domain of IgG for Mouse FcgammaRII,” Molecular Immunology, 29(1):53-59.
[cited by applicant]
Lund et al. (1995) “Oligosaccharide-protein interactions in IgG can modulate recognition by Fcgamma receptors,” The FASEB Journal 9:115-119.
[cited by applicant]
Lund et al. (1996) “Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains,” J. Immunol.…
[cited by applicant]
Lutterbach et al. (2007) “Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival,” Cancer Research. 67(5):2081-2088.
[cited by applicant]
MacCallum et al. (1996) “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography,” J. Mol. Biol., 262:732-745.
[cited by applicant]
Martin et al. (2001) “Crystal Structure at 2.8 A of an FcRn/Heterodimeric Fc Complex Mechanism of pH-Dependent Binding,” Molecular Cell, 7:867-877.
[cited by applicant]
Massachusetts General Hospital (Dec. 10, 2012) “Suppremol's Sm101 shows a sustained clinical activity and a favorable safety profile in primary immune thrombocytopenia (ITP) patients,” Press Release. Evaluate Ltd.
[cited by applicant]
Medesan et al. (1997) “Delineation of the amino acid residues involved in transcytosis and catabolismof mouse LgG,” J. Immunol. 158:2211-2217.
[cited by applicant]
Mendell et al. (2001) “Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy,” Neurology. 56:445-449.
[cited by applicant]
Meriggioli et al. (2009) “Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity,” Lancet Neurol. 8:475-490.
[cited by applicant]
Mezo et al. (2008) “Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn,” Proc. Natl. Acad. Sci. USA. 105(7):2337-2342.
[cited by applicant]
Mi et al. (2008) “Targeting the neonatal Fc receptor for antigen delivery using engineered Fc fragments,” J. Immunol. 181:7550-7561.
[cited by applicant]
Mohamed et al. (Jan. 7, 2013) “Massive intravascular haemolysis after high dose intravenous immunoglobulin therapy,” British Journal of Haematology. 160:570.
[cited by applicant]
Montoyo et al. (2009) “Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice,” Proc. Natl. Acad. Sci. USA. 106:2788-2793.
[cited by applicant]
Morea et al. (2000) “Antibody Modeling: Implications for Engineering and Design,” Methods, 20:267-279.
[cited by applicant]
Newburger et al. (2004) “Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Car…
[cited by applicant]
Newland et al. (1983) “High-dose intravenous IgG in adults with autoimmune thrombocytopenia,” The Lancet, 84-87.
[cited by applicant]
Nieswandt et al. (1999) “Acute systemic reaction and lung alterations induced by an antiplatelet integrin gpIIb/IIIa antibody in mice,” Blood. 94:684-693.
[cited by applicant]
Niknami et al. (Jun. 2013) “Beneficial effect of a multimerized immunoglobulin Fc in an animal model of inflammatory neuropathy (experimental autoimmune neuritis),” J. Peripher. Nerv. Syst. 18(2):141-52.
[cited by applicant]
Ober et al. (2004) “Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level,” Proc. Natl. Acad. Sci. USA. 101:11076-11081.
[cited by applicant]
Ober et al. (2004) “Visualizing the site and dynamics of IgG salvage by the MHC Class I-related receptor, FcRn,” J. Immunol. 172:2021-2029.
[cited by applicant]
Oshima et al. (1998) “Characterization of murine CD70 by molecular cloning and mAb,” Int. Immunol. 10(4):517-526.
[cited by applicant]
Patel et al. (2011) “Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model,” J. Immunol. 187(2):1015-1022.
[cited by applicant]
Pevzner et al. (2011) “Anti-LRP4 autoantibodies in AChR-and MuSK-antibody-negative myasthenia gravis,” J. Neurol., 9 pages.
[cited by applicant]
Prabhat et al. (2007) “Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy,” Proc. Natl. Acad. Sci. USA. 104:5889-5894.
[cited by applicant]
Presta et al. (2002) “Engineering therapeutic antibodies for improved function,” Biochemical Society Transactions, 30(4):487-490.
[cited by applicant]
Reddy et al. (2000) “Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4,” J. Immunol., 164:1925-1933.
[cited by applicant]
Roopenian et al. (2003) “The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs,” J. Immunology. 170:3528-3533.
[cited by applicant]
Roopenian et al. (2007) “FcRn: the neonatal Fc receptor comes of age,” Nat. Rev. Immunol. 7(9):715-725.
[cited by applicant]
Roux et al. (1998) “Comparisons of the Ability of Human IgG3 Hinge Mutants, IgM, IgE, and IgA2, to Form Small Immune Complexes: A Role for Flexibility and Geometry,” The Journal of Immunology, 4083-4090.
[cited by applicant]
Schwab et al. (Mar. 2013) “Intravenous immunoglobulin therapy: how does IgG modulate the immune system?” Nat. Rev. Immunol. 176(13).
[cited by applicant]
Seidling et al. (2013) “Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events,” Acta Derm Venereol. 93:34…
[cited by applicant]
Semple (2010) “Animal models of immune thrombocytopenia (ITP),” Annals of Hematology. 89:37-44.
[cited by applicant]
Sesarman et al. (2010) “The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases,” Cell. Mol. Life Sci. 67(15):2533-2550.
[cited by applicant]
Sewell: Ed. (Jan. 22, 2010) First National Immunoglobulin Database Report. Department of Health.
[cited by applicant]
Shelton (1999) “Acquired myasthenia gravis: what we have learned from experimental and spontaneous animal models,” Veterinary Immunology and Immunopathology. 69:239-249.
[cited by applicant]
Shields et al. (2001) “High Resolution Mapping of the Binding Site on Human IgG1 for FcgammaRI, FcgammaRII, FcgammaRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcgammaR,” The Journal of Biolog…
[cited by applicant]
Sockolosky et al. (2015) “The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy,” Advanced Drug Delivery Reviews, 91:109-124.
[cited by applicant]
Soliven (2012) “Autoimmune neuropathies: insights from animal models,” Journal of the Peripheral Nervous System. 17:28-33.
[cited by applicant]
Sorde et al. (2017) “Massive immune response against IVIg interferes with response against other antigens in mice: A new mode of action?,” PLoS ONE, 12(10):e0186046, 15 pages.
[cited by applicant]
Stamos et al. (2004) “Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor,” EMBO J. 23(12):2325-2335.
[cited by applicant]
Swiercz et al. (May 27, 2014) “Use of Fc-engineered antibodies as clearing agents to increase contrast during PET,” J. Nucl. Med. 55:1204-1207.
[cited by applicant]
Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America, et al. (2000) “Myasthenia gravis,” Neurology, 55:16-23.
[cited by applicant]
Tramontano et al. (1990) “Framework Residue 71 is a Major Determinant of the Position and Conformation of the Second Hypervariable Region in the VH Domains of Immunoglobulins,” J. Mol. Biol., 215:175-182.
[cited by applicant]
Ulrichts et al. (May 2017) “ARGX-113: Towards a Safe and Selective Elimination of Pathogenic Autoantibodies,” 13th International Conference on Myasthenia Gravis and Related Disorders, May 15-17, 2017. New York, New York…
[cited by applicant]
Ulrichts et al. (2018) “Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans,” J. Clin. Invest., 128(1):4372-4386.
[cited by applicant]
Vaccaro et al. (2005) “Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels,” Nat. Biotechnol. 23(10):1283-1288.
[cited by applicant]
Vaccaro et al. (2006) “Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies” Proc. Natl. Acad. Sci. USA. 103(49):18709-18714.
[cited by applicant]
Van Der Meche et al. (1992) “A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group,” N. Engl. J. Med. 326:1123-1129.
[cited by applicant]
Wani et al. (2006) “Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene,” Proc. Natl. Acad. Sci. USA. 103(13):5084-5989.
[cited by applicant]
Woods et al. (1984) “Autoantibodies against platelet glycoprotein lb in patients with chronic immune thrombocytopeniarpura,” Blood. 64:156-160.
[cited by applicant]
Written Opinion corresponding to International Patent Application No. PCT/EP2013/068399, mailed Apr. 14, 2014.
[cited by applicant]
Xu et al. (2000) “In Vitro Characterization of Five Humanized OKT3 Effector Function Variant Antibodies,” Cellular Immunology, 200:16-26.
[cited by applicant]
Yang et al., (2011) “Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China,” Journal of Neurological Sciences, 301:71-76, 2011.
[cited by applicant]
Ying et al. (2012) “Soluble Monomeric IgG1 Fc,” The Journal of Biological Chemistry, 287(23):19399-19408.
[cited by applicant]
Ying et al. (2013) “Engineered Soluble Monomeric IgG1 CH3 Domain,” The Journal of Biological Chemistry, 288 (35):25154-25164.
[cited by applicant]
Zhang et al. (2012) “Autoantibodies to Lipoprotein-Related Protein in Patients With Double-Seronegative Myasthenia Gravis,” Arch Neurol, 69(4):445-451.
[cited by applicant]
Zhou et al. (2003) “Generation of mutated variants of the human form of the MHC class I-related receptor, FcRn, with increased affinity for mouse immunoglobulin G,” J. Mol. Biol. 332:901-913.
[cited by applicant]
Zhou et al. (2005) “Conferring the binding properties of the mouse MHC Class I related receptor, FcRn, onto the human ortholog by sequential rounds of site-directed mutagenesis,” J. Mol. Biol. 345:1071-1081.
[cited by applicant]
Zinman et al. (2007) “IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial,” Neurology 68:837-841.
[cited by applicant]
U.S. Appl. No. 16/893,863, filed Jun. 5, 2020, Filip Borgions.
[cited by applicant]
Azevedo, “argenx Doses First Subject in Study Evaluating Subcutaneous ARGX-113 for Autoimmune Diseases.” Myasthenia Gravis News. 2017;1-2.
[cited by applicant]
Bas Van Der Woning, “R&D Day: Fifth Efgartigimod Indication: Myositis,” ARGENX, Jul. 20, 2021, pp. 23-37.
[cited by applicant]
Basta and Dalakas, “High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments,” J Clin Invest. 1994;94(5):1729…
[cited by applicant]
Dalakas et al., “High-dose intravenous immune globulin for stiff-person syndrome,” N Engl J Med. 2001;345(26):1870-6.
[cited by applicant]
Dalakas, “Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy,” Neurotherapeutics. 2021;18(4):2397-24…
[cited by applicant]
Daugherty Ann Let al: “Chapter 8: Formulation and delivery issues for monoclonal antibody therapeutics”, Jan. 1, 2010 (Jan. 1, 2010), Current Trends in Monoclonal Antibody Development and Manufacturing, Springer, US, pp…
[cited by applicant]
Heo, “Efgartigimod: First Approval,” Drugs. 2022;82(3):341-348.
[cited by applicant]
Howard et al., “A double-blind placebo-controlled study to evaluate safety and efficacy of FcRn antagonist ARGX-113 (efgartigimod) in generalized myasthenia gravis,” Elsevier 70th Annual Meeting of the American Academmy…
[cited by applicant]
Julien et al., “Abstract No. L10 Efgartigimod Prevents Necrosis and Allows for Muscle Fiber Regeneration in a Humanized Mouse Model of Immune-mediated Necrotizing Myopathy (IMNM),” ACR Meeting Abstracts, ACR Conference …
[cited by applicant]
Kiessling, “Safety, Pharmacokinetics and Pharmacodynamics of the FCRN Inhibitor UCB7665: A Phase I Study,” Journal of the Peripheral Nervous System. 2017;22(3):226-414.
[cited by applicant]
Miyagawa, “Idiopathic Thrombocytopenia Purpura,” Mebio. 2017;34(6):102-107.
[cited by applicant]
PCT Search Report and Written Opinion for PCT/EP2023/054065, mailed May 3, 2023.
[cited by applicant]
Verschuuren, “A double-blind placebocontrolled study to evaluate safety and efficacy of forn antagonist ARGX-113 in generalized MG,” Elsevier Science Publishers, Amsterdam, NL, 2018.
[cited by applicant]
Wang et al., “Antibody structure, instability, and formulation,” J Pharm Sci. 2007;96(1):1-26.
[cited by applicant]
Response to Final Office Action as Filed in U.S. Appl. No. 15/064,195 dated Jul. 28, 2023.
[cited by applicant]
Tavakolpour, Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?, Int Immunopharmacol. 2017;53:133-142.
[cited by applicant]
“Assignment submission for U.S. Appl. No. 61/920,547 confirming change of legal form of arGEN-X B.V. to arGEN-X N.V. on May 28, 2014”, Document D30 submitted with Notice of Opposition for European Patent No. 3087095 (Ap…
[cited by applicant]
“Auxiliary Request 1—Annotated Version” for European Patent No. 3087095 (Application No. 14827372.5), dated Oct. 28, 2020, 5 pages.
[cited by applicant]
“Auxiliary Request 1—Clean Version” for European Patent No. 3087095 (Application No. 14827372.5), dated Oct. 28, 2020, 5 pages.
[cited by applicant]
“Auxiliary Request 2—Annotated Version” for European Patent No. 3087095 (Application No. 14827372.5), dated Oct. 28, 2020, 5 pages.
[cited by applicant]
“Auxiliary Request 2—Clean Version” for European Patent No. 3087095 (Application No. 14827372.5), dated Oct. 28, 2020, 4 pages.
[cited by applicant]
“Declaration of Pieter Spuijbroek”, Document D42 submitted with Reply to Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated Oct. 28, 2020, 5 pages.
[cited by applicant]
“Main Request—Annotated Version” for European Patent No. 3087095 (Application No. 14827372.5), dated Oct. 28, 2020, 5 pages.
[cited by applicant]
“Main Request—Clean Version” for European Patent No. 3087095 (Application No. 14827372.5), dated Oct. 28, 2020, 5 pages.
[cited by applicant]
“Sequence Alignment of Seq ID No. 22 from D6 and Seq ID Nos. 1, 2, and 3 from the Patent”, Document D32 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020…
[cited by applicant]
“Sequence Alignment of Seq ID Nos. 1-3 from Patent and corresponding portion of Uniprot ID: P01857”, Document D24 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated M…
[cited by applicant]
“UniProtKB—P01857 (IGHG1_HUMAN)”, Document D43 submitted with Reply to Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated Oct. 28, 2020, 6 pages.
[cited by applicant]
Allen et al., “Efgartigimod in chronic inflammatory demyelinating polyneuropathy: Adhere phase 2 trial design”, Muscle and Nerve Oct. 1, 2020 John Wiley and Sons Inc. NLD, Oct. 1, 2020, 62(Suppl. 1):abstract(1 page).
[cited by applicant]
Anonymous, “A Randomized, Double-Blinded, Placebo-Controlled Trial of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus)”, Jul. 16, 2021, Retrieved from the Internet: URL:https://rctportal.nip…
[cited by applicant]
Anonymous, “Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 Sc Administered Subcutaneously in Patients With Generalized Myasthenia Gravis (ADAPTSC+)”, Mar. 27, 2021, ClinicalTrials.gov, Retrieved f…
[cited by applicant]
Anonymous, “History of Changes for Study: NCT05267600, A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (BALLAD)”, Apr. 14, 2022, p. 1-7.
[cited by applicant]
Anthony et al., “Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc”, Science, Apr. 18, 2008, 320(5874):373-376.
[cited by applicant]
Antohe et al., “Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells,” Human Immunol., 2001, 62:93-105.
[cited by applicant]
Arduin et al., “Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a”, 2015, Molecular Immunology, 63:456-463.
[cited by applicant]
Balighi et al., “Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?”, Archives of Dermatological Research, Dec. 1, 2018, 311(1):63-69.
[cited by applicant]
Bitonti et al., “Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway,” Proc. Natl. Acad. Sci. USA, 2004, 101:9763-9768.
[cited by applicant]
Blumberg et al., “Anitbodies in the breakdown lane,” Nature Biotechnology, 2005, 23(10):1232-1234.
[cited by applicant]
Brinkhaus Maximilian et al., “The Fab region of IgG impairs the internalization pathway of FcRn upon Fc management,” Nature Communications, 2022, 13(1):6073(14 pages).
[cited by applicant]
Broome C. et al., “Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients with Primary Immune Thrombocytopenia: Advance SC, a Global Phase 3 Clinical Trial in Progress” [abstract]. Res Pract Thromb Haem…
[cited by applicant]
Bruhns et al., “Colony-Stimulating Factor-1-Dependent Macrophages are Responsible for IVIG Protection in Antibody-Induced Autoimmune Disease”, Immunity, Apr. 2003, 18(4):573-581.
[cited by applicant]
Brych et al., “Characterization of antibody aggregation: role of buried, unpaired cysteines in particle formation”, J Pharm Sci., Feb. 2010, 99(2):764-781.
[cited by applicant]
Bystryn and Jiao, “IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris”, Autoimmunity, vol. 39, No. 7, pp. 601-607, Nov. 2006 (Nov. 2006).
[cited by applicant]
Burmeister et al., “Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor,” Nature, 1994, 372(6504):336-343.
[cited by applicant]
Bussel et al., “Eltrombopag for the treatment of chronic idiopathic thrombocytopenia purpura,” N Engl J Med., 2007, 357(22):2237-2247.
[cited by applicant]
Carter, “Potent antibody therapeutics by design”, Nat Rev Immunol., May 2006, 6(5):343-357.
[cited by applicant]
Challa et al., “Neonatal Fc receptor expression in macrophages is indispensable for IgG homeostasis,” MAbs., 2019, 11(5):848-860 doi: 10.1080/19420862.2019.1602459. Epub Apr. 30, 2019.
[cited by applicant]
ClinicalTrials.gov, “A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients with Pemphigus”, ClinicalTrials.gov Identifier: NCT03334058, Nov. 7, 2017, 8 pages.
[cited by applicant]
ClinicalTrials.gov, “A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients with Pemphigus”, ClinicalTrials.gov Identifier: NCT04598477, Oct. 22, 2020, 10 pages.
[cited by applicant]
Dalakas et al., “A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis,” N Engl J Med., 1993, 329(27):1993-2000.
[cited by applicant]
Dall'Acqua et al., “Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences,” J. Immunol., 2002, 169:5171-5180.
[cited by applicant]
Dall'Acqua et al., “Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn),” J. Biol. Chem., 2006, 281:23514-23524.
[cited by applicant]
Deisenhofer, “Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from
[cited by applicant]
Dick Jr. et al., “C-Terminal Lysine Variants in Fully Human Monoclonal Antibodies: Investigation of Test Methods and Possible Causes”, Biotechnology and Bioengineering, 2008, 100(6):1132-1143.
[cited by applicant]
Dickinson et al., “Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line,” J. Clin. Invest., Oct. 1999, 104(7):903-911.
[cited by applicant]
Dimitrov, “Engineered CH2 domains (nanoantibodies)”, MAbs, Jan.-Feb. 2009, 1(1):26-28.
[cited by applicant]
Evoli et al., “Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase”, Autoimmunity Review, 2013, 12:931-935.
[cited by applicant]
Firan et al., “The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans”, Int. Immunol., 2001, 13(8):993-1002.
[cited by applicant]
Ghanima et al., “Pharmacokinetic / Pharmacodynamic (PK/PD) Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocyt…
[cited by applicant]
Ghetie et al., “FcRn: the MHC class I-related receptor that is more than an IgG transporter”, Immunol Today, 1997, 18(12):592-598.
[cited by applicant]
Ghetie et al., “Multiple roles for the major histocompatibility complex class I-related receptor FcRn”, Annu. Rev. Immunol., 2000, 18:739-766.
[cited by applicant]
Goh et al., “Impact of host cell line choice on glycan profile”, Crit Rev Biotechnol., Sep. 2018, 38(6):851-867.
[cited by applicant]
Gomez-Guerrero et al., “Administration of IgG Fc Fragments Prevents Glomerular Injury in Experimental Immune Complex Nephritis”, J Immunol., Feb. 15, 2000, 164(4):2092-2101.
[cited by applicant]
Guidance for Industry Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers FDA, Jul. 2005, pp. 1-27. (Year: 2005), 30 pages.
[cited by applicant]
Ha et al., “Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins”, Frontiers in Immunology, 2016, 7(394):1-16.
[cited by applicant]
Hans-Hartmut et al., “Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations”, J Allergy Clin Immunol, Sep. 1, 2020, 146(3):479-491.
[cited by applicant]
Hinton et al., “Engineered human IgG antibodies with longer serum half-lives in primates,” J. Biol. Chem., 2004, 279:6213-6216.
[cited by applicant]
Howard et al., “Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis”, Neurology, 2019, 92(23):1-8.
[cited by applicant]
Israel et al., “Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn,” Immunolgy, 1996, 89:573-578.
[cited by applicant]
Janeway et al., “Immunobiology: the immune system in health and disease”, 6th Garland Science, New York, 2005, 5 pages.
[cited by applicant]
Jefferis et al., “Human immunoglobulin allotypes: possible implications for immunogenicity”, MAbs, Jul.-Aug. 2009, 1(4):332-338.
[cited by applicant]
Joshi et al., “An Update on Disease Modifying Antirheumatic Drugs”, Inflammation & Allergy—Drug Targets, 2014, 13:249-261.
[cited by applicant]
Kabat et al., “In: Sequences of proteins of immunological interest”, U.S. Department of Health and Human Services, 1991, (Title Page and Table of Contents), 11 pages.
[cited by applicant]
Kabat et al., “Unusual Distributions of amino Acids in Complementarity-determining (Hypervariable) Segments of Heavy and Light Chains of Immunoglobulins and Their Possible Roles in Specificity of Antibody-combining Site…
[cited by applicant]
Kaneko et al., “Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation”, Science, Aug. 4, 2006, 313(5787):670-673.
[cited by applicant]
Kasperkiewicz et al., “Pemphigus.” Nat Rev Dis Primers., 2017, 3:17026(40 pages).
[cited by applicant]
Kasprick et al., “Treatment with anti-neonatal Fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in mice”, British Journal of Pharmacology, Wiley-Blackwell, Mar. 6, 2020, 177(10):2381-…
[cited by applicant]
Khan et al., “Clinical Practice Updates in the Management of Immune Thrombocytopenia,” P & T., 2017, 42(12):756-763.
[cited by applicant]
Kiessling Peter et al, “The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study”, Science Translational Medicine, Nov. 1, 2017, 9(414):1-12.
[cited by applicant]
Kim et al., “Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor,” Eur. J. Immunol., 1994, 24:2429-2434.
[cited by applicant]
Kobayashi et al., “FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells”, Am. J. Physiol. Renal Physiol., 2002, 282:F358-F365.
[cited by applicant]
Li et al., “Myasthenia gravis: newer therapies offer sustained improvement”, Cleveland Clinic Journal of Medicine, 2013, 80(11):711-721.
[cited by applicant]
Ishii-Watabe et al., “Molecular Design of Therapeutics Monoclonal Antibodies,” Journal of Pharmaceutical Science and Technology, Japan, 2014, 74(1):4-11.
[cited by applicant]
Maho-Vaillant et al., “FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus”, Frontiers in Immunology, M…
[cited by applicant]
Matt Hoffman, “Subcutaneous Efgartigimod Shows Noninferiority to IV Formulation in Generalized Myasthenia Gravis”, Mar. 23, 2022, Neurology, Retrieved from the Internet:URL:https://web.archive.org/web/20220326043901/htt…
[cited by applicant]
McCarthy et al., “Bidirectional transcytosis of IgG by the rat neonatal Fc receptor expressed in a rat kidney cell line: a system to study protein transport across epithelia”, J. Cell Sci., 2000, 113:1277-1285.
[cited by applicant]
Medesan et al., “Comparative studies of rat IgG to further delineate the Fc:FcRn interaction site,” Eur. J. Immunol., 1998, 28:2092-2100.
[cited by applicant]
Michael F. Halle, “Converting Intravenous Dosing to Subcutaneous Dosing with Recombinant human Hyaluronidase”, Pharmaceutical Technology, Advanstar Communications Inc., Oct. 2, 2007, 31(10):10 pages.
[cited by applicant]
Newland et al., “Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia,” Am J Hematol., 2020, 95(2):178-187.
[cited by applicant]
Nih, A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus), Oct. 22, 2020, Retrieved from the Internet: URL:https://we…
[cited by applicant]
Popov et al., “The stoichiometry and affinity of the interaction ofmurine Fc fragments with the MHC class I-related receptor, FcRn,” Mol. Immol., 1996, 33:521-530.
[cited by applicant]
Putnam et al., “Proteins in Multiple Myeloma: VIII. Biosynthesis of Abnormal Proteins”, J Biol Chem., Apr. 1958, 231(2):671-684.
[cited by applicant]
Pyzik et al., “The Neonatal Fc Receptor (FcRn): A Misnomer?”, Front Immunol., Jul. 10, 2019, 10:1540(24 pages).
[cited by applicant]
Raghavan et al., “Analysis of the pH Dependence of the Neonatal Fc Receptor/Immunoglobulin G Interaction Using Antibody and Receptor Variants,” Biochemistry, 1995, 34:14649-14657.
[cited by applicant]
Robak et al, “Single-Agent Ibrutinib Vs Chemoimmunotherapy Regimens for Treatment-Naive Patients with Chronic Lymphocytic Leukemia (CLL): A Cross-Trial Comparison”, Blood, 2017, 130(Suppl. 1):1750(6 pages).
[cited by applicant]
Robak et al., “Efficacy and Safety of a new intravenous immunoglobulin 10% formulation (octagam 10%) in patients with immune throbmbocytopenia”, Hematology, 2010, 15(5):351-359.
[cited by applicant]
Robak et al., “Phase II, Multiple-Dose Study of Anti-FcRn Antibody, Rozanolixizumab (UCB7665), in Patients with Primary Immune Thrombocytopenia: Interim Analysis”, Blood, Dec. 7, 2017, 130(Suppl. 1):15(8 pages), 59th An…
[cited by applicant]
Rosenwasser et al., “Anti-CD23”, Clinical Reviews in Allergy and Immunology, 2005, 29:61-72.
[cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity”, Proc. Natl. Acad. Sci. USA, 1982, 79(6):1979-1983.
[cited by applicant]
Samuelsson et al., “Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor”, Science, Jan. 19, 2001, 291(5503):484-486.
[cited by applicant]
Schwab et al., “Intravenous immunoglobulin therapy: how does IgG modulate the immune system?”, Nat. Rev. Immunol., Mar. 2013, 13(3):176-189.
[cited by applicant]
Shang et al., “Modular protein expression by RNA trans-splicing enables flexible expression of antibody formats in mammalian cells from a dual-host phage display vector”, Protein Engineering, Design & Selection, 2015, 2…
[cited by applicant]
Silvestri et al., “Treatment-Refractory Myasthenia Gravis”, Journal of Clinical Neuromuscular Disease, 2014, 15(4):167-178.
[cited by applicant]
Spiekermann et al., “Receptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult Life: Functional Expression of FcRn in the Mammalian Lung”, J. Exp. Med., 2002, 196(3):303-310.
[cited by applicant]
Ulrichts et al., “Supplemental data Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans”, J. Clin. Invest., 2018, 128(10):4372-4386.
[cited by applicant]
Van Faassen et al., “Serum albumin-binding VHHs with variable pH sensitivities enable tailored half-life extension of biologics,” FASEB J., 2020, 34(6):8155-8171. doi: 10.1096/fj.201903231R. Epub Apr. 28, 2020.
[cited by applicant]
Vitetta et al., “Considering therapeutic antibodies”, Science, Jul. 21, 2006, 313(2):308-309.
[cited by applicant]
Wang, “Protein aggregation and its inhibition on biopharmaceutics”, International Journal of Pharmaceutics, Jan. 31, 2005, 289(1-2):1-30.
[cited by applicant]
Ward et al., “Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn”, Chapter 4, Adv. Immunol., 2009, 103:77-115.
[cited by applicant]
Weiner et al., “Tunable antibodies”, Nature Biotechnology, May 2005, 23(5):556-557.
[cited by applicant]
Wittlin et al. “Pharmacokinetic/Pharmacodynamic Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia”, Br…
[cited by applicant]
Yoshida et al., “Human Neonatal Fc Receptor Mediates Transport of IgG into Luminal Secretions for Delivery of Antigens to Mucosal Dendritic Cells,” Immunity, 2004, 20:769-783.
[cited by applicant]
Cited By (3)